{"pub": "afr", "url": "https://afr.com/street-talk/shaws-beats-drum-for-recce-pharma-placement-20191008-p52ykq", "downloaded_at": "2019-10-08 01:25:20.904852+00:00", "title": "Shaws beats drum for Recce Pharma placement", "language": "en", "text": "Synthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fresh funds for the company on Tuesday.\n\nShaw was seeking buyers for 15.5 million new Recce shares at 26\u00a2 each on Tuesday morning, in a placement to raise $4 million.\n\nThe deal was priced at a 17.5 per cent discount to the last close and a 20 per cent discount to the five day VWAP, according to terms sent to potential investors.\n\nFunds raised were pegged for clinical trials.\n\nRecce is as ASX-listed health company that told investors it is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.\n\nThe company had a $33.7 million market capitalisation prior to the raising.\n\nShaw was calling for bids by 9am Perth time on Wednesday.", "description": "Synthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fresh funds for the company on Tuesday.", "authors": [], "top_image": "https://static.ffx.io/images/$zoom_0.5298%2C$multiply_0.7554%2C$ratio_1.777778%2C$width_1059%2C$x_0%2C$y_0/t_crop_custom/e_sharpen:25%2Cq_85%2Cf_auto/a674e7a507dd077af80affda06591c125d35de7b", "published_at": "2019-10-08"}